Fate Therapeutics shareholders approve 2022 Stock Plan, elect all director nominees

FATE THERAPEUTICS INC

Stockholders approved 2022 Stock Option and Incentive Plan with 61.5M for, 23.2M against, 84.7K abstain.
Class III directors Coughlin, Wolchko, and Agarwal elected; Agarwal received 69.7M for, 15.0M withheld.
Ratification of Ernst & Young as auditor for FY2022 passed with 90.1M for, 69K against.
Non-binding advisory vote on executive compensation passed with 75.4M for, 9.1M against.
Broker non-votes of 5.5M shares on director election, say-on-pay, and plan approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.